Applied Therapeutics — Technical Presentation (April 2020)
39 slides from Applied Therapeutics's technical presentation, Apr 21, 2020
Slide 1: ACTION-Galactosemia: April 2020 Trial Results
ACTION - GALACTOSEMIA: April 2020 Trial Results Development of AT - 007 for the Treatment of Galactosemia Riccardo Perfetti , MD, PhD Chief Medical Officer
Slide 2: Summary: ACTION-Galactosemia Study Results
Summary: ACTION - Galactosemia Study Results 2 Safety/ PK/ PD • AT - 007 was safe and well - tolerated • PK/PD data supports once - daily oral dosing • AT - 007 is CNS penetrant – important in Galactosemia, which includes significant CNS clinical presentation Efficacy in Galactosemia Patients • AT -
Slide 3: Overview of Galactosemia
Overview of Galactosemia =) APPLIED, folition
Slide 4: Overview of Galactosemia
AT - 007 for Treatment of Galactosemia • Rare genetic metabolic disease caused by inability to break down galactose • Galactose is a natural sugar formed by metabolism of lactose, but is also produced endogenously by the body • In patients with Galactosemia, Aldose Reductase converts galactose to ga
Slide 5: Galactosemia Clinical Presentation
Galactosemia Clinical Presentation • Hepatic and renal failure • Brain swelling (edema; encephalopathy) • Potentially life threatening if not identified and managed immediatel y 5 Acute Newborn • CNS complications • Low IQ/ intellectual impairment • Motor skills • Speech/ language • Learning, behavi
Slide 6: Galactosemia Patient Population and Regulatory Pathway
Galactosemia Effects ~2,800 Patients in the US; Potential for Abbreviated Regulatory Approval & Low Burden of Development • ~2,800 living US patients ; ~80 new births per year • Majority of patients are under the age of 40, as newborn screening was adopted in the 1980s and 1990s • Regulatory pathway
Slide 7: Aldose Reductase Activity Causes Toxic Accumulation of Galactitol
Aldose Reductase Activity Causes Toxic Accumulation of Galactitol in Galactosemia Galactose Aldose Reductase Galactitol Toxic Aberrant Metabolite GALK TYPE II GALT Classic Galactosemia Gal - 1 - Phosphate Glu - 1 - Phosphate • Galactosemia results in accumulation of galactose, which becomes an aberr
Slide 8: CNS-Penetrant Aldose Reductase Inhibitor Prevents Galactitol Formation
AT - 007, a CNS - Penetrant Novel Aldose Reductase Inhibitor, Prevents Galactitol Formation and Accumulation Galactose Aldose Reductase Galactitol Toxic Aberrant Metabolite GALK TYPE II GALT Classic Galactosemia Gal - 1 - Phosphate Glu - 1 - Phosphate • Galactosemia results in accumulation of galact
Slide 9: Galactosemia Preclinical Data
Galactosemia Preclinical Data
Slide 10: GALT Deficient Rat Model Closely Mirrors Human Disease
0 1 2 3 4 5 6 7 Liver Brain Plasma GALT Deficient Rat Model Closely Mirrors Human Disease 10 Biochemical Effects Tissue Deposition of Galactitol CNS Outcomes 0 1 2 3 4 5 Liver Brain Plasma Galactose pmol Galactitol pmol Wild Type GALT null GALT null WT All GALT null rats display cataracts (caused by
Slide 11: Treatment Corrects All 3 Aspects of Disease in Rat Model
Cataract Severity Score Dose AT - 007 (mg/kg) 0 0.5 1 1.5 2 0 200 400 600 800 1000 AT - 007 Treatment Corrects All 3 Aspects of Disease in the Galactosemia Rat Model 11 Biochemical Effects Tissue Deposition of Galactitol CNS Outcomes Wild Type GALT null Placebo GALT null (placebo) WT AT - 007 treatm
Slide 12: Significantly Reduces Galactitol Levels in all Target Tissues
A Closer Look: AT - 007 Significantly Reduces Galactitol Levels in all Target Tissues Without Increasing Galactose or Gal - 1P • AT - 007 treatment from neonatal Day 1 to Day 10 significantly reduced galactitol in liver, brain and plasma • AT - 007 treatment did not increase galactose or Gal1P level
Slide 13: Clinical Program: ACTION-Galactosemia Trial April 2020 Data
Clinical Program: ACTION - Galactosemia Trial April 2020 Data
Slide 14: Galactosemia Phase 1/2 Registrational Study Design
Galactosemia Phase 1/2 Registrational Study (ACTION - Galactosemia) Multi - Center Placebo - Controlled Study in Healthy Volunteers & Adult Galactosemia Patients Single Ascending Dose (n=40) 14 Multiple Ascending Dose (n=40, 7 days) 5 mg/kg single dose 5 mg/kg 27 Days Daily Dosing (n=4) Adult Galact
Slide 15: Healthy Volunteer Data: Safe and Well Tolerated
15 • AT - 007 was safe and well tolerated at all doses, including 40mg/kg • No treatment - related discontinuations • Dose - dependent increase in exposure • PK results supportive of once daily oral dosing Healthy Volunteer Data AT - 007 Was Safe and Well Tolerated; PK Supports Once - Daily Dosing
Slide 16: Brain Penetrant, Important Given CNS Complications
AT - 007 is Brain Penetrant Important in Galactosemia Given CNS Complications 16 AT - 007 CSF concentration (ng/ml) Dose - Dependent Increase in CSF Concentration in Healthy Volunteers (via lumbar puncture) AT - 007 Dose (in mg/kg) 0 10 20 30 40 50 5mg 20mg 40mg
Slide 17: Adult Galactosemia Patient Baseline Demographics
ACTION - Galactosemia Trial Data Adult Galactosemia Patient Baseline Demographics
Slide 18: Baseline Demographic and Diagnostic Characteristics
18 Baseline Demographic and Diagnostic Characteristics (n=11*) Broad Age Range, Multiple Genetic Mutations Represented Subject Age Gender Ethnicity BMI Gene mutation Urine galactitol (mM/urine creatine mol/L) Baseline Plasma galactitol (ng/ml) Baseline GALT enzyme activity (Mmol/h/mg) 2003 - 101 33
Slide 19: Baseline Clinical and Descriptive Characteristics
19 Galactosemia Patient Baseline Clinical & Descriptive Characteristics (n=11*) CNS Disorders Psychiatric Disorders Seizures (n=5) Anxiety (n=4) Dementia (n=1) Depression (n=3) Encephalopathy (n=1) ADHD (n=3) Tremor Clinical Characteristics Patient Quality of Life Living with family members or proxi
Slide 20: MRI/MRS Baseline Characteristics
MRI/MRS Baseline Characteristics • Brain morphology changes caused by galactitol - induced osmotic dysregulation • Galactitol was present and quantifiable in the brain of all adult Galactosemia patients (absent in healthy adults) • N - acetyl - aspartate, a marker of neuronal health, was markedly de
Slide 21: Pharmacokinetics and Safety Data in Galactosemia Patients
ACTION - Galactosemia Trial Data AT - 007 Pharmacokinetics and Safety Data in Galactosemia Patients
Slide 22: Pharmacokinetic Results Support Once Daily Dosing
22 Pharmacokinetic Results Support Once Daily Dosing in Galactosemia Patients • Plasma PK parameters of AT - 007 support once daily oral dosing • PK profile in Galactosemia patients was similar to healthy volunteers, suggesting similar drug metabolism and clearance • PK profile suggests no first pas
Slide 23: Adverse Event Summary
SYSTEM ORGAN CLASS PREFERRED TERM NUMBER (%) OF PATIENTS, NUMBER OF EVENTS Placebo N=4 AT - 007 (5 mg/kg) N=4 AT - 007 (20 mg/kg) N=4 Overall N=12* Significance Any Adverse Event 1 (25.0), 3 3 (75.0), 6 2 (50.0), 2 6 (50.0), 11 Not Significant Cardiac Disorders 1 (25.0), 1 0 (0.0), 0 0 (0.0), 0 1 (8
Slide 24: Detailed Laboratory Findings
24 Detailed Laboratory Findings No Drug - Related Changes in Hepatic or Renal Function PARAMETER/VISIT Placebo N=4 AT - 007 5 mg/kg N=4 AT - 007 20 mg/kg N=4 Significance ALT (U/L) – Mean (SD) Baseline 21.50 (7.00) 17.75 (9.0) 18.25 (9.07) Not Significant Post - Dosing (Day 32) 23.00 (10.15) 14.5 (8
Slide 25: Safety and PK Summary in Galactosemia Patients
Safety and PK Summary in Galactosemia Patients Pharmacokinetics • PK supports once - daily dosing • Linear increase in AT - 007 dose - dependent plasma concentration • Similar exposure levels in Galactosemia patients and healthy volunteers Safety • AT - 007 was safe and well - tolerated • N o treatm
Slide 26: Efficacy Results in Galactosemia Patients
ACTION - Galactosemia Trial Data AT - 007 Efficacy Results in Galactosemia Patients
Slide 27: Significantly Reduced Plasma Galactitol in Dose-Dependent Fashion
27 -1400 -1200 -1000 -800 -600 -400 -200 0 PBO 5mg/kg 20 mg/kg Plasem Galactitol (ng/ml) Maximum Galactitol Reduction AT - 007 Treatment Significantly Reduced Plasma Galactitol Levels in Adult Galactosemia Patients in a Dose - Dependent Fashion
Slide 28: Decreased Galactitol Levels in All Treated Patients
28 AT - 007 Decreased Galactitol Levels in All Treated Patients Galactitol Reduction Was Rapid and Sustained Reduction in Galactitol at 5mg/kg ~20% Reduction in Galactitol at 20mg/kg ~50% -70.0% -60.0% -50.0% -40.0% -30.0% -20.0% -10.0% 0.0% Baseline DAY 1 DAY 12 DAY 32-34 % Change from BL Maximum G
Slide 29: Galactitol Reduction Maintained Throughout Treatment Period
29 AT - 007 Reduction in Galactitol Was Maintained Throughout the 24 - Hour Treatment Period, Supporting Once Daily Dosing 1,000 1,200 1,400 1,600 1,800 2,000 2,200 2,400 2,600 2,800 0HR 0.5HR 1HR 1.5HR 2HR 4HR 6HR 8HR 12HR 24HR Plasma Galactitol (ng/ml) Hours post - dosing on Day 12 Plasma Galactit
Slide 30: Treatment Does Not Increase Galactose Levels
30 Treatment with AT - 007 Does Not Increase Galactose Levels Supports Pre - Clinical Data Demonstrating AT - 007 Does Not Cause Derangement of Galactose or Other Galactose Pathway Metabolites 0 100 200 300 400 500 600 700 800 900 1,000 0HR 0.5HR 1HR 1.5HR 2HR 4HR 6HR 8HR 12HR 24HR Plasma Galactose
Slide 31: MRI/MRS Results
MRI/MRS Results MRI • AT - 007 treated patients demonstrated a trend towards decreased ventricular volume, a measure of edema (brain swelling) MRS • AT - 007 treated patients (4 out 6)* demonstrated decreased galactitol levels in the brain • AT - 007 treated patients (4 out of 6) demonstrated an imp
Slide 32: A Closer Look at Seizures
A Closer Look at Seizures 32 Seizures • 5 patients had a history of seizures (generalized onset) • All 5 patients were maintained on antiepileptic medications • 4 patients had < 1 seizure per year • 1 patient had > 1 seizure per month • Due to the low frequency of seizures in the majority of patient
Slide 33: Future Development Plans
ACTION - Galactosemia Trial Data AT - 007 for Treatment of Galactosemia: Future Development Plans
Slide 34: Extension Study: Designed to Confirm Long-Term Safety
AT - 007 Extension Study: Designed to Confirm Long - Term Safety • 90 Day Safety Extension • Open to those who participated in 28 - day core study and new patients • Placebo - controlled; 3:1 randomization (active to placebo) • Active dose flexible to allow 20mg/kg and potentially 40mg/kg • Safety m
Slide 35: Adult European Study Cohort
Adult European Study Cohort to Recruit GALK - Deficient Patients and Support EU Approval • Primarily designed to recruit GALK deficient patients • More prevalent in Europe, but still extremely rare • Display similar CNS complications to Classic Galactosemia (GALT - deficient) patients • Secondary ob
Slide 36: Proposed Pediatric Study
Proposed AT - 007 Pediatric Study (Under Discussion with FDA) 36 Proposed Study Design • 2 - Part Multiple Dose Study • Several age groups investigated • 2 – 6 • 7 – 12 • 13 <18 • Children 2 months – 2 yrs may be added following initial safety data (newborns/ infants) Study Objectives • Safety • Dos
Slide 37: Summary & Conclusions
ACTION - Galactosemia Trial Data Summary & Conclusions
Slide 38: Summary: ACTION-Galactosemia Study Results
Summary: ACTION - Galactosemia Study Results 38 Safety/ PK/ PD • AT - 007 was safe and well - tolerated • PK/PD data supports once - daily oral dosing • AT - 007 is CNS penetrant – important in Galactosemia, which includes significant CNS clinical presentation Efficacy in Galactosemia Patients • AT
Slide 39: Thank you
Thank you Font c THER APE
Applied Therapeutics — Technical Presentation (April 2020) on 6ix